LivingGLP1
Study S001876

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor)

Included trial: extracted dataClinicalTrials.gov record

Registration

Registration
NCT01930188
Acronym
SUSTAIN™ 2
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
DOUBLE
Status
COMPLETED
Enrollment
1231
Start
2013-12-02
Primary completion
2015-10-12
Lead sponsor
Novo Nordisk A/S
Conditions
Diabetes; Diabetes Mellitus, Type 2
Interventions
DRUG:semaglutide; DRUG:sitagliptin; DRUG:placebo
Results posted
TRUE
Secondary identifiers
EUDRACT_NUMBER:2012-004827-19; OTHER:U1111-1135-8730; OTHER:132366; REGISTRY:CTRI/2014/05/004626

Registered primary outcomes

  • Change in HbA1c (Glycosylated Haemoglobin) From Baseline [Week 0, week 56]

Linked records (16)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0020952Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study.
Pulleyblank R, PharmacoEconomics - open
2023Nonrandomized studyPMID 37178435DOIcites ClinicalTrials.gov:NCT01930188; registry reference DERIVED:37178435
R0012216Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10.
Capehorn M, Diabetes therapy : research, treatment and education of diabetes and related disorders
2020Randomized trialPMID 32193837DOIcites ClinicalTrials.gov:NCT01930188; registry reference DERIVED:32193837
R0015927Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials.
DeSouza C, The Journal of clinical endocrinology and metabolism
2020Randomized trialPMID 31769496DOIcites ClinicalTrials.gov:NCT01930188; registry reference DERIVED:31769496
R0018492Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
Lingvay I, The Journal of clinical endocrinology and metabolism
2020Systematic reviewPMID 32827435DOIcites ClinicalTrials.gov:NCT01930188; registry reference DERIVED:32827435
R0018529Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
Husain M, Cardiovascular diabetology
2020Randomized trialPMID 32998732DOIcites ClinicalTrials.gov:NCT01930188; registry reference DERIVED:32998732
R0018857Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
Husain M, Diabetes, obesity & metabolism
2020OtherPMID 31903692DOIcites ClinicalTrials.gov:NCT01930188; registry reference DERIVED:31903692
R0009827GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES.
Rodbard HW, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2019Other trialPMID 30865526DOIregistry reference BACKGROUND:30865526
R0012485Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.
Jendle J, Diabetes, obesity & metabolism
2019Other trialPMID 31215727DOIcites ClinicalTrials.gov:NCT01930188; cites EudraCT:2012-004827-19; registry reference DERIVED:31215727
R0013158Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR, Diabetes & metabolism
2019Other trialPMID 30615985DOIregistry reference RESULT:30615985
R0017746Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide.
Fonseca VA, The Journal of clinical endocrinology and metabolism
2019OtherPMID 30938762DOIregistry reference BACKGROUND:30938762
R0013229Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis.
Carlsson Petri KC, Diabetes therapy : research, treatment and education of diabetes and related disorders
2018Other trialPMID 29907893DOIcites ClinicalTrials.gov:NCT01930188; registry reference RESULT:29907893
R0018825Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials.
Ahrén B, Diabetes, obesity & metabolism
2018Randomized trialPMID 29766634DOIregistry reference RESULT:29766634
R0020727Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes.
Petri KCC, Diabetes, obesity & metabolism
2018Randomized trialPMID 29748996DOIregistry reference RESULT:29748996
R0023345Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme.
DeVries JH, Diabetes, obesity & metabolism
2018Randomized trialPMID 29862621DOIregistry reference RESULT:29862621
R0025617Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.
Sharma R, Current medical research and opinion
2018Systematic reviewPMID 29764222DOIregistry reference RESULT:29764222
R0021907Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B, The lancet. Diabetes & endocrinology
2017Randomized trialPMID 28385659DOIcites ClinicalTrials.gov:NCT01930188; registry reference RESULT:28385659